Status:
COMPLETED
Staccato Zaleplon Single Dose Pharmacokinetics
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers
Eligibility Criteria
Inclusion
- Male and female subjects between the ages of 18 to 55 years, inclusive who are in good general health
Exclusion
- Subjects with a history of allergy or intolerance to zaleplon. Subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00620620
Start Date
February 1 2008
End Date
March 1 2008
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Unit Inc.
Evansville, Indiana, United States, 47714